<DOC>
	<DOCNO>NCT02314637</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy MP-513 ( Teneligliptin ) monotherapy combination Sulfonylurea ( glimepiride ) Japanese patient type 2 Diabetes 52 week administration .</brief_summary>
	<brief_title>Long-term Safety Study MP-513 Monotherapy Combination With Sulfonylurea Japanese Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>In case combination therapy Sulfonylurea , patient receive stable dose regimen sulfonylurea diabetes 12 week administration investigational drug Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug HbA1c criterion : monotherapy : 6.9 % 10.5 % combination therapy Sulfonylurea : 7.4 10.5 % Patients administer diabetes therapeutic drug prohibit concomitant use within 12 week administration investigational drug . Patients type 1 diabetes , diabetes mellitus cause pancreas impairment , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients accept treatment arrhythmias Patients serious diabetic complication Patients excessive alcohol addict Patients severe hepatic disorder severe renal disorder Patients pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>DPP-IV inhibitor</keyword>
</DOC>